Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06479239

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer (Panc 002)

Phase I/II Study of Anti-CD3 x Anti-EGFR Bispecific Antibody (EGFRBi) Armed Fresh Peripheral Blood Mononuclear Cells (EGFR FPBMC) in Metastatic or Unresectable Pancreatic Cancer

Sponsor: University of Virginia

Conditions Pancreas Cancer Pancreatic Cancer

Interventions EGFR FPBMC

Updated 7 times since 2024 Last updated: Mar 11, 2026 Started: Nov 6, 2024 Primary completion: Dec 31, 2027 Completion: Jun 30, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Pancreas Cancer and Pancreatic Cancer, this trial is actively recruiting participants. The trial is conducted by University of Virginia and has accumulated 7 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Jan 2026 — Mar 2026 [monthly]

Recruiting PHASE1/PHASE2
Jan 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Jan 2025 [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Oct 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

▶ Show 2 earlier versions

Aug 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Virginia

Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States